Frank X Leonard sold $231k of NVCR
Chief Executive Officer at NovoCure Ltd. 16,966 shares at an average of $13.59, traded Feb 27, 2026, filed Mar 3, 2026.
Score components
- +25RoleCEO
- +13Trade size$231k at market
- 0Share of holdings soldSold 4.9% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -20.7%, 3m +18.9%, 6m +30.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001822879-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | SOpen-market sale Ordinary Shares | -9,734 | $13.66 | $133k | 338,011 | Mar 3, 2026 |
| Feb 28, 2026 | AGrant or award Ordinary Shares | +18,621 | $0.00 | $0 | 356,632 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Ordinary Shares | -7,232 | $13.49 | $98k | 349,400 | Mar 3, 2026 |
Related signals
Other insiders at NovoCure Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | NovoCure Ltd | Frank X Leonard Chief Executive Officer | $615k 34,273 shares | -7% | |
| 41Moderate | NovoCure Ltd | Jeryl L Hilleman director | $46k 2,945 shares | -18% | |
| 41Moderate | NovoCure Ltd | David Hung director | $46k 2,945 shares | -13% | |
| 36Weak | NovoCure Ltd | Gabriel Leung director | $46k 2,945 shares | -3% | |
| 36Weak | NovoCure Ltd | W Anthony Vernon director | $46k 2,945 shares | -1% | |
| 41Moderate | NovoCure Ltd | Timothy J Scannell director | $46k 2,945 shares | -17% | |
| 41Moderate | NovoCure Ltd | Allyson J Ocean director | $46k 2,945 shares | -21% | |
| 41Moderate | NovoCure Ltd | Kristin Stafford director | $46k 2,945 shares | -21% | |
| 46Moderate | NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $85k 6,412 shares | -3% | |
| 64Notable | NovoCure Ltd | William F Doyle Executive Chairman | $933k 71,887 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.